MARKET

NUZTF

NUZTF

Neurizon Therapeutics
OTCMQB
0.070
NaN%
Opening 09:30 12/05 EST
OPEN
--
PREV CLOSE
0.070
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.100
52 WEEK LOW
0.070
MARKET CAP
37.43M
P/E (TTM)
-3.1390
1D
5D
1M
3M
1Y
5Y
1D
Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer
Reuters · 11/26 23:17
Elanco in licensing pact with Australia’s Neurizon
Seeking Alpha · 07/03 11:40
About NUZTF
Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Webull offers Neurizon Therapeutics Ltd stock information, including OTCMQB: NUZTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUZTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUZTF stock methods without spending real money on the virtual paper trading platform.